Overview

Ocular Inflammation in Cataract Patients and Response to Treatment With Xiidra

Status:
Enrolling by invitation
Trial end date:
2022-09-25
Target enrollment:
Participant gender:
Summary
To determine if the use of Xiidra® reduces ocular surface inflammation in preoperative and postoperative cataract patients.
Phase:
Phase 4
Details
Lead Sponsor:
Bucci Laser Vision Institute
Treatments:
Lifitegrast
Ophthalmic Solutions